A5004470985- Cholangiocarcinoma and Gallbladder Cancer Studies
- Liver Disease Diagnosis and Treatment
- Gallbladder and Bile Duct Disorders
- Pediatric Hepatobiliary Diseases and Treatments
- Liver Diseases and Immunity
- Hepatocellular Carcinoma Treatment and Prognosis
- Cell death mechanisms and regulation
- Liver physiology and pathology
- Pancreatic and Hepatic Oncology Research
- Hepatitis B Virus Studies
- Viral-associated cancers and disorders
- Drug Transport and Resistance Mechanisms
- Drug-Induced Hepatotoxicity and Protection
- Liver Disease and Transplantation
- Peptidase Inhibition and Analysis
- MicroRNA in disease regulation
- Hepatitis C virus research
- Endoplasmic Reticulum Stress and Disease
- Cancer Mechanisms and Therapy
- Organ Transplantation Techniques and Outcomes
- RNA modifications and cancer
- Phagocytosis and Immune Regulation
- Hippo pathway signaling and YAP/TAZ
- Alcohol Consumption and Health Effects
- Transplantation: Methods and Outcomes
WinnMed
2016-2025
Mayo Clinic in Arizona
2016-2025
Mayo Clinic
2016-2025
Macquarie University
2024
The University of Queensland
2024
Mayo Clinic in Florida
1990-2024
Mayo Clinic Hospital
2023
The Geneva Association
2023
European Association for the Study of the Liver
2023
University of Minnesota Rochester
1999-2022
Cholangiocarcinoma (CCA) comprises a heterogeneous group of cancers with pathologic features biliary tract differentiation, and is presumed to arise from the intra- or extrahepatic tract. Two recent papers suggest these may also directly transdifferentiation hepatocytes [1,2]. Gallbladder cancer distinct cholangiocarcinoma in epidemiology, pathobiology, clinical presentation management, should be considered different form [3].
This guideline has been approved by the American Association for Study of Liver Diseases and represents position Association. These recommendations provide a data-supported approach. They are based on following: (1) formal review analysis recently-published world literature topic (Medline search); (2) College Physicians Manual Assessing Health Practices Designing Practice Guidelines1; (3) policies, including AASLD Policy Development Use Guidelines Gastroenterological Statement Guidelines2;...
Nonalcoholic fatty liver disease (NAFLD) is a serious health problem. Although NAFLD represents form of lipotoxicity, its pathogenesis remains poorly understood. The aim this study was to examine the cellular mechanisms involved in free acid (FFA)-mediated hepatic lipotoxicity. FFA treatment cells resulted Bax translocation lysosomes and lysosomal destabilization with release cathepsin B (ctsb), cysteine protease, into cytosol. This process also partially dependent on ctsb. Lysosomal nuclear...
TNF-α–induced apoptosis is thought to involve mediators from acidic vesicles. Cathepsin B (cat B), a lysosomal cysteine protease, has recently been implicated in apoptosis. To determine whether cat contributes apoptosis, we exposed mouse hepatocytes the cytokine vitro and vivo. Isolated treated with TNF-α presence of transcription inhibitor actinomycin D (AcD) accumulated their cytosol. Further experiments using cell-free systems indicated that caspase-8 caused release active purified...
Elevated serum free fatty acids (FFAs) and hepatocyte lipoapoptosis are features of non-alcoholic liver disease. However, the mechanism by which FFAs mediate is unclear. Because JNK activation pivotal in both metabolic syndrome accompanying disease cellular apoptosis, we examined role FFA-induced lipoapoptosis. Multiple cell lines primary mouse hepatocytes were treated culture with monounsaturated saturated acids. Despite equal steatosis, apoptosis greater during exposure to versus FFAs....
Compare survival after neoadjuvant therapy and liver transplantation with resection for patients hilar CCA.
Non-alcohol-induced steatohepatitis (NASH) is characterized by elevated serum aminotransferase activities with hepatic steatosis, inflammation, and occasionally fibrosis that may progress to cirrhosis. No established treatment exists for this potentially serious disorder. Our aim was conduct a pilot study evaluate the safety estimate efficacy of ursodeoxycholic acid (UDCA) clofibrate in NASH. Forty patients were diagnosed NASH based on compatible liver biopsy other causes disease, including...